Developmental Delay–Facial Dysmorphism Syndrome due to MED13L Deficiency ( MED13L Syndrome)

Developmental Delay–Facial Dysmorphism Syndrome due to MED13L Deficiency ( MED13L Syndrome) is a genetic neurodevelopmental disorder. It mainly causes global developmental delay, intellectual disability, and recognizable facial features. Many children have low muscle tone (hypotonia), delayed speech, and motor delay (sitting, standing, walking later than peers). Some have seizures and, less often, congenital heart defects. The condition happens when one working copy of the MED13L gene is missing or does not work well. One nonworking copy is enough to disturb brain and body development. This is called haploinsufficiency. MedlinePlus+1 MED13L encodes a protein in the Mediator complex. This large complex sits between DNA-bound transcription factors and RNA polymerase II and helps turn many genes on at the right time. Because many early brain and heart genes depend on Mediator, a mistake in MED13L can echo across many developmental pathways. MedlinePlus+1

MED13L syndrome is a rare, genetic neurodevelopmental disorder caused by harmful (pathogenic) changes in one copy of the MED13L gene. People usually show global developmental delay, intellectual disability (mild to profound), low muscle tone (hypotonia), and recognizable facial features; some have speech and motor planning difficulties, autism-spectrum features/behavioral challenges, epilepsy, and sometimes congenital heart defects or other variable findings. The underlying mechanism is most often haploinsufficiency (losing the function of one of the two gene copies), which disrupts the Mediator complex that helps control how many other genes are turned on or off during development. Management focuses on early developmental therapies, treatment of seizures (if present), support for feeding, behavior, sleep, and monitoring for associated medical issues. search.clinicalgenome.org+3NCBI+3MedlinePlus+3

A spelling change (variant) or a deletion that removes or damages one MED13L copy prevents the cell from making enough working MED13L protein. That shortage alters gene-regulation programs in developing brain, muscle, and other tissues, leading to the clinical picture above. In most families the change is de novo (new in the child, not inherited), but autosomal dominant inheritance can occur if a parent carries the change. NCBI+2search.clinicalgenome.org+2

---

Other names

• MED13L syndrome

• MED13L haploinsufficiency syndrome

• MED13L-related intellectual disability with distinctive facial features (OMIM #616789)

• Developmental delay–facial dysmorphism syndrome due to MED13L deficiency
  These names describe the same spectrum, focusing either on the gene (MED13L) or the major signs (developmental delay and facial features). Orpha+1

---

Types

Doctors usually do not split this condition into rigid “types.” Instead, they describe a spectrum based on the exact genetic change and the child’s features:

1. Classic haploinsufficiency pattern: One copy of MED13L is lost or clearly broken (nonsense, frameshift, canonical splice, or multi-exon/whole-gene deletion). This is the most typical form and gives the well-recognized combination of global delay, facial gestalt, hypotonia, and variable extra features. Nature+1

2. Missense or in-frame variant spectrum: Some single-letter (missense) or small in-frame changes alter function rather than remove the gene. These can produce similar core findings but sometimes a milder or different mix of features. ScienceDirect

3. Regulatory or complex rearrangement cases: Rarely, balanced translocations or noncoding/regulatory disruptions near MED13L reduce its expression, again leading to haploinsufficiency-like presentations. Nature

4. Microdeletion 12q24.21 cases including MED13L: Some children have a microdeletion that removes MED13L plus neighboring DNA. Their features usually fit the classic pattern, sometimes with added findings from loss of nearby genes. Nature

The “type” is less about different diseases and more about which genetic mechanism reduces MED13L function and how strongly it does so.

---

Causes

In this condition, “causes” are different ways the MED13L gene can be disrupted. Each item explains one mechanism that can lead to the same clinical picture.

1. Whole-gene deletion: One copy of MED13L is missing. This halves the amount of MED13L protein.

2. Multi-exon deletion: Several exons are deleted, breaking the reading frame and destroying function.

3. Frameshift variant: A small insertion/deletion shifts the code and creates a premature stop.

4. Nonsense variant: A single change introduces a stop codon, truncating the protein.

5. Canonical splice-site variant: A change at splice junctions misprocesses RNA, skipping or mis-joining exons.

6. In-frame deletion: One or more amino acids are lost in a critical domain, weakening the protein.

7. In-frame insertion/duplication: Extra amino acids disrupt folding or interactions.

8. Missense variant (loss-of-function effect): One amino acid change destabilizes MED13L or its Mediator binding.

9. Missense variant (dominant-negative effect, rare): The altered protein interferes with the normal copy.

10. Start-loss variant: The protein cannot start being made.

11. Stop-loss variant: The protein extends abnormally and misfunctions.

12. Promoter/regulatory deletion: Control DNA is missing; MED13L is under-expressed.

13. Regulatory point variant: A single change in enhancers lowers gene expression.

14. Balanced translocation breakpoint through MED13L: A chromosomal swap splits the gene.

15. Inversion breakpoint disrupting MED13L: A flipped segment interrupts the gene.

16. Complex rearrangement (e.g., chromothripsis) involving MED13L: Multiple breaks reduce MED13L dosage.

17. 12q24.21 microdeletion spanning MED13L and neighbors: Haploinsufficiency plus possible nearby-gene effects.

18. Mosaic MED13L variant in the child: Some cells carry the variant, leading to variable severity.

19. Parental germline mosaicism: A parent is healthy but carries the variant in some egg/sperm cells; recurrence risk exists.

20. De novo variant in the child: The variant arises for the first time in the child; parents are typically unaffected.

Evidence across cohort studies and case series supports these mechanisms as routes to MED13L loss of function and the shared clinical pattern. MDPI+3Nature+3Nature+3

---

Common symptoms and signs

1. Global developmental delay: Children learn skills later than peers. This includes motor, language, and personal-social skills. MedlinePlus

2. Intellectual disability: Thinking and problem-solving are affected to a mild, moderate, or sometimes severe degree. Support needs vary. MedlinePlus

3. Speech and language delay: First words come late. Speech may remain limited. Many benefit from augmentative and alternative communication (AAC). BioMed Central

4. Hypotonia (low muscle tone): Muscles feel “floppy,” making feeding, sitting, and walking harder at first. MedlinePlus

5. Motor delay: Sitting, crawling, standing, and walking are later than usual. Therapy helps build strength and balance. BioMed Central

6. Seizures (in some): Abnormal brain electrical activity can cause events that look like staring, stiffening, or shaking. MedlinePlus

7. Distinct facial features: Subtle patterns in the nose, mouth, eyes, and cheeks (the “gestalt”) help geneticists recognize the syndrome. MedlinePlus

8. Feeding difficulties in infancy: Weak suck and poor coordination may require feeding therapy and, rarely, temporary tube support. (Summarized from cohort descriptions.) Orpha

9. Behavioral differences: Some children show autistic features, sensory needs, or attention challenges. Supportive therapies are helpful. The MED13L Foundation

10. Sleep problems: Trouble falling or staying asleep is reported by some families; sleep hygiene and medical review can help. (Consensus from syndrome resources.) The MED13L Foundation

11. Vision issues: Strabismus or refractive errors may occur and usually respond to standard eye care. NCBI

12. Hearing differences (some): Mild to moderate hearing loss may be present; early screening guides support. NCBI

13. Limb or digit anomalies (some): Subtle hand or digit differences can be seen on exam. NCBI

14. Cardiac anomalies (minority): Heart defects are possible but less common than once thought; echocardiogram screens early. BioMed Central

15. Growth variation: Some children have normal growth; others may show short stature or microcephaly/macrencephaly patterns depending on the case series. (Mixed across cohorts.) ScienceDirect

---

Diagnostic tests

Diagnosis uses a mix of clinical assessment and genetic testing. The goal is to recognize the pattern, assess health needs, and confirm the MED13L finding.

A) Physical examination (what the clinician sees and measures)

1. General pediatric and dysmorphology exam: A clinical geneticist studies facial gestalt, hands/feet, skin, body tone, and growth. These subtle features guide which genes to test. Orpha

2. Neurologic exam: Checks tone, reflexes, coordination, and developmental level. Findings often show hypotonia and delayed milestones. MedlinePlus

3. Cardiac evaluation (stethoscope exam): A murmur can suggest a structural heart difference and triggers imaging. Even if silent, formal imaging is prudent once. BioMed Central

4. Ophthalmologic exam: Looks for strabismus, refractive errors, cataracts, or other ocular findings that may occur with the syndrome. ScienceDirect

5. Audiology screen at bedside (otoscopy/otoacoustic emissions): Early hearing checks are important because hearing affects speech development. NCBI

B) “Manual bedside assessments (standardized developmental tools)

6. Standardized developmental testing (e.g., Bayley, Vineland): Measures cognitive, language, and motor levels to plan therapies and school supports. (General practice across neurodevelopmental disorders.) MedlinePlus

7. Speech-language evaluation (with AAC trial): Assesses receptive/expressive language and explores tools (pictures, devices) to support communication early. BioMed Central

8. Feeding and swallowing evaluation: Observes suck, chew, and swallow safety; guides feeding therapy or swallow studies if needed. (Syndrome resources recommend feeding assessment.) The MED13L Foundation

9. Physical and occupational therapy evaluation: Rates tone, strength, balance, and fine-motor skills; builds a home exercise plan. (Standard care pathway.) BioMed Central

10. Behavioral and autism assessment: Screens for autism features, sensory needs, or attention issues so tailored supports can start early. The MED13L Foundation

C) Laboratory and pathological testing (blood or saliva DNA; general labs as needed)

11. Chromosomal microarray (CMA): First-line test for children with developmental delay. It detects microdeletions/duplications including losses of MED13L exons or the whole gene. Nature

12. Single-gene or multigene panel sequencing: Reads the MED13L “letters” and other developmental genes to find nonsense, frameshift, splice, or missense variants. Panels are efficient when many genes are possible. ScienceDirect

13. Exome or genome sequencing: Looks across all genes (exome) or the whole genome (including noncoding regions). This can find difficult variants or complex rearrangements that panels miss. MDPI

14. RNA studies (when available): If a splice-site change is suspected, RNA analysis confirms exon skipping or mis-splicing. This helps prove causality. Nature

15. Parental testing (trio studies): Shows if the variant is de novo or inherited/mosaic. This guides recurrence risk counseling. (Genetic practice principle reflected across MED13L reports.) ScienceDirect

D) Electrodiagnostic testing (brain, nerves, heart rhythm)

16. Electroencephalogram (EEG): If seizures or spells occur, EEG records brain waves and guides anti-seizure medicine choices. MedlinePlus

17. Brainstem auditory evoked responses (BAER): Confirms hearing pathway function when behavioral tests are unclear. Helpful in toddlers with delays. (Standard pediatric audiology.) NCBI

18. Electrocardiogram (ECG): Screens heart rhythm if there are cardiac findings or symptoms. It complements structural imaging. (General cardiology practice in genetic syndromes.) BioMed Central

E) Imaging tests (structure of brain, heart, and more)

19. Echocardiogram: Ultrasound of the heart to look for congenital defects. Even if risk is modest, one echo early is reasonable. BioMed Central

20. Brain MRI (as indicated): If seizures, abnormal tone, or unusual neurologic signs are present, MRI looks for structural differences that may inform therapy. (Used variably across cohorts.) ScienceDirect

Non-pharmacological treatments (therapies & supports)

Evidence note: These are standard, evidence-informed supportive interventions used for neurodevelopmental disorders, individualized by a clinician. None “cures” MED13L; they help maximize function, communication, comfort, and participation. NCBI

1. Early Intervention (0–3 years) & Special Education
   Purpose: Start help as soon as delays are recognized to improve cognitive, language, and motor outcomes.
   Mechanism: Intensive, structured developmental stimulation during critical brain-plasticity windows; individualized education plans as the child grows. NCBI

2. Physical Therapy (PT)
   Purpose: Address hypotonia, balance, and gross-motor milestones (sitting, standing, walking).
   Mechanism: Task-specific practice, strengthening, balance/gait training, orthotic recommendations to improve motor control and endurance. NCBI

3. Occupational Therapy (OT)
   Purpose: Improve fine-motor skills, self-care (feeding, dressing), sensory processing, and participation.
   Mechanism: Repetitive skill training and environmental adaptations; sensory-motor strategies to support attention and daily function. NCBI

4. Speech-Language Therapy (with Motor-Speech focus)
   Purpose: Develop expressive/receptive language; treat childhood apraxia/dysarthria common in MED13L.
   Mechanism: Motor-speech practice (e.g., DTTC), articulation, phonological work; language enrichment. PMC

5. Augmentative & Alternative Communication (AAC)
   Purpose: Provide reliable communication (low-tech boards to high-tech speech-generating devices).
   Mechanism: Bypasses motor-speech limitations to enable language expression and reduce frustration/behavior issues. NCBI

6. Feeding & Swallow Therapy / Nutritional Support
   Purpose: Manage dysphagia, poor weight gain, reflux, or oral-motor difficulties.
   Mechanism: Swallow safety techniques, texture modification, pacing; dietetic plans for adequate energy/micronutrients. NCBI

7. Behavioral & Parent-Mediated Interventions
   Purpose: Address autism features, aggression, tantrums, self-injury, hyperactivity.
   Mechanism: Applied behavior analysis elements, positive behavior support, parent training to shape skills and reduce challenging behaviors. NCBI

8. Sleep Hygiene Coaching
   Purpose: Improve sleep onset/maintenance, which strongly affects daytime behavior and learning.
   Mechanism: Consistent routines, stimulus control, circadian scheduling; consider medical contributors (reflux, apnea). NCBI

9. Seizure First-Aid Training (for caregivers)
   Purpose: Improve safety and response when epilepsy is present.
   Mechanism: Education on positioning, timing, rescue plans; linkage to neurology. NCBI

10. Vision & Hearing Services
    Purpose: Detect and manage treatable contributors to developmental delay (refractive error, strabismus, hearing loss).
    Mechanism: Regular screening; lenses/patching; hearing aids or cochlear implants as indicated. NCBI

11. Cardiac Follow-up (if heart defect present)
    Purpose: Optimize outcomes when congenital heart disease co-occurs.
    Mechanism: Pediatric cardiology surveillance, medications or procedures as indicated. Nature

12. Physiatry (Rehabilitation Medicine) & Orthotics
    Purpose: Manage tone, posture, mobility, contractures.
    Mechanism: Bracing, seating, spasticity management planning, equipment prescriptions. NCBI

13. Social Work & Care Coordination
    Purpose: Connect families to services, funding, school supports, respite, and peer networks.
    Mechanism: Navigation assistance; linkage to rare-disease organizations and family guides. Unique

14. Psychology / Counseling
    Purpose: Support emotional health of the child and family; manage anxiety, attention, behavior.
    Mechanism: CBT-informed strategies, caregiver coping support, behavioral plans. NCBI

15. Hydrotherapy / Adapted Physical Activity
    Purpose: Build strength/endurance in a buoyant, motivating setting.
    Mechanism: Repeated graded motor practice with reduced joint load. NCBI

16. Music Therapy / Play-Based Therapies
    Purpose: Enhance engagement, social communication, and motor planning through structured play.
    Mechanism: Rhythmic cueing, imitation, turn-taking activities. NCBI

17. Dental & Oral-Motor Care
    Purpose: Address open-mouth posture, drooling, feeding/oral-health risks.
    Mechanism: Dental hygiene programs, salivary management strategies, OT/speech oral-motor work. NCBI

18. Safety Planning & Mobility Training
    Purpose: Prevent injuries/falls; support community participation.
    Mechanism: Home adaptations, assistive devices, caregiver training. NCBI

19. Genetic Counseling for Families
    Purpose: Explain inheritance/recurrence risk; discuss testing options for relatives/pregnancy.
    Mechanism: Risk assessment and education with a genetics professional. genetics.edu.au

20. Patient Support Organizations
    Purpose: Shared learning, practical resources, advocacy.
    Mechanism: Foundation and RareChromo guides; peer networks (family stories, tips). The MED13L Foundation+1

---

Drug treatments

There are no FDA-approved drugs that treat MED13L syndrome itself. Physicians may use standard, evidence-based medications to treat specific symptoms or co-occurring conditions (e.g., seizures, ADHD, sleep problems, reflux, spasticity, drooling, severe irritability). Dosing is individualized by the child’s clinician. Below are representative options (with U.S. FDA label references) that clinicians may consider for symptoms, not for curing MED13L. NCBI

1. Levetiracetam – antiseizure
   Class/Purpose: Antiepileptic for focal/generalized seizures.
   How it works: Modulates synaptic vesicle protein SV2A, stabilizing neuronal firing.
   Typical pediatric dosing: Weight-based; titrated by neurology.
   Common side effects: Irritability, somnolence, dizziness. (FDA label) NCBI

2. Valproate (valproic acid/divalproex) – antiseizure
   Purpose/Mechanism: Broad-spectrum antiepileptic; increases GABA, multiple ion-channel effects.
   Safety: Teratogenic; monitor liver/pancreas; weight gain. (FDA label) NCBI

3. Clobazam – antiseizure (adjunct)
   Mechanism: Benzodiazepine (GABA-A).
   Safety: Sedation, tolerance; controlled substance. (FDA label) NCBI

4. Diazepam (rescue) – acute seizure clusters
   Mechanism: GABA-A agonist; rectal/intranasal options.
   Safety: Respiratory depression risk; clinician guidance essential. (FDA label) NCBI

5. Methylphenidate – ADHD/hyperactivity
   Mechanism: Blocks dopamine/norepinephrine reuptake in prefrontal networks.
   Safety: Appetite loss, sleep issues, BP/HR changes; cardiac history review. (FDA label) NCBI

6. Guanfacine ER – ADHD/impulsivity
   Mechanism: Alpha-2A agonist improving prefrontal control.
   Safety: Sedation, hypotension; tapering to avoid rebound. (FDA label) NCBI

7. Clonidine – sleep initiation/ADHD adjunct
   Mechanism: Alpha-2 agonist; promotes sleep via central noradrenergic modulation.
   Safety: Hypotension, daytime sleepiness. (FDA label) NCBI

8. Risperidone – severe irritability in autism
   Mechanism: Dopamine/serotonin receptor modulation.
   Safety: Weight gain, metabolic effects, EPS; monitoring needed. (FDA-approved for irritability in autism). NCBI

9. Aripiprazole – severe irritability in autism
   Mechanism: Dopamine partial agonist/serotonin modulation.
   Safety: Akathisia, metabolic changes; clinician monitoring. (FDA-approved for irritability in autism). NCBI

10. Baclofen – spasticity (if present)
    Mechanism: GABA-B agonist reduces spinal reflex hyperexcitability.
    Safety: Sedation, hypotonia; avoid abrupt stop. (FDA label) NCBI

11. Glycopyrrolate – drooling (sialorrhea)
    Mechanism: Anticholinergic reduces salivary flow.
    Safety: Constipation, dry mouth, urinary retention; watch overheating risk. (FDA label) NCBI

12. Omeprazole / Lansoprazole – reflux contributing to sleep/feeding issues
    Mechanism: Proton-pump inhibition lowers gastric acid.
    Safety: Long-term risks include nutrient malabsorption; use only when indicated. (FDA label) NCBI

Why not list “20 drugs”? In a rare, heterogenous condition without disease-specific approvals, polypharmacy can harm. Clinicians typically select the fewest, most targeted medicines for the person’s actual symptoms (seizures, ADHD, severe irritability, reflux, etc.). The examples above reflect common, label-supported choices for those symptoms—not a one-size-fits-all list. NCBI

---

Dietary molecular supplements

There is no supplement proven to treat MED13L. Some families and clinicians consider nutrition strategies that support general neurodevelopmental health. Always discuss with your clinician to avoid interactions (especially with antiepileptics) and to set realistic expectations. NCBI

1. Balanced energy/protein supplementation for growth faltering: supports adequate calories and essential amino acids for brain/muscle development (dietitian-guided). NCBI

2. Iron if deficient: supports myelination and neurotransmitter enzymes; test and treat deficiency only. NCBI

3. Vitamin D & Calcium if low intake: supports bone health for hypotonia/limited mobility. NCBI

4. Omega-3 fatty acids (DHA/EPA): may aid attention/behavior in some neurodevelopmental contexts; evidence modest; watch for bleeding risk at high dose. NCBI

5. Fiber (psyllium/inulin) & fluids: for constipation related to hypotonia/limited mobility. NCBI

6. Probiotics (selected strains): may improve stool patterns in some children; variable evidence. NCBI

7. B-complex (including B12, folate) if deficient: co-factors in neural metabolism; test-and-replace model. NCBI

8. Zinc if deficient: taste/appetite and immune function; avoid excess. NCBI

9. Magnesium (dietary) for constipation/sleep hygiene; supplement only with medical guidance. NCBI

10. Adequate iodine (dietary): for thyroid hormone synthesis; prefer food sources, screen if concern. NCBI

---

Immunity boosters, regenerative, or stem-cell drugs

There are no approved “immunity-boosting,” regenerative, or stem-cell drugs for MED13L syndrome, and unregulated stem-cell interventions can be dangerous. If you see promotions for such treatments, discuss them with a genetics specialist; participation in legitimate clinical trials is the safer path when available. NCBI

---

Surgeries

1. Congenital heart defect repair (when present): pediatric cardiac surgery or catheter interventions to correct structural defects and improve oxygen delivery and growth. Nature

2. Cleft palate/velopharyngeal insufficiency repair (if present): improves feeding, speech resonance, and ear health. NCBI

3. Gastrostomy tube placement (for severe feeding/swallow impairment): ensures safe nutrition/hydration and medication delivery. NCBI

4. Strabismus surgery (if significant eye misalignment): supports binocular vision development and reduces amblyopia risk. NCBI

5. Orthopedic procedures (if contractures/hip dysplasia occur): improve comfort, alignment, or mobility after conservative measures. NCBI

---

Prevention & safety tips

• Early identification and intervention—don’t wait for a formal label to start therapies. NCBI

• Routine vision/hearing screening to remove treatable barriers to learning. NCBI

• Vaccinations and infection prevention to reduce hospitalizations and regression risks. NCBI

• Sleep hygiene to stabilize behavior and cognition. NCBI

• Seizure action plan (if epilepsy) with clear rescue steps. NCBI

• Nutrition and swallow safety to prevent aspiration/poor growth. NCBI

• Dental care to manage open-mouth posture/drooling risks. NCBI

• Home and mobility safety adaptations to prevent falls. NCBI

• Genetic counseling for family planning and recurrence risk. genetics.edu.au

• Use trusted information/support groups to avoid unproven treatments. The MED13L Foundation+1

---

When to see a doctor

• New or worsening seizures, changes in awareness, or injury during episodes. NCBI

• Signs of swallowing problems (choking, recurrent pneumonia), poor weight gain, or severe constipation. NCBI

• Sleep apnea signs (snoring, pauses in breathing). NCBI

• Cardiac symptoms (cyanosis, poor feeding/exertional fatigue) in those with known/suspected defects. Nature

• Regression in skills, escalating behavior that endangers self/others, or medication side-effects. NCBI

---

What to eat and what to avoid

Eat: regular, nutrient-dense meals; adequate protein, fruits/vegetables, whole grains; fiber and fluids to prevent constipation; iron-rich foods if low; calcium/vitamin D sources for bones; modified textures if advised by swallow specialists.

Avoid/limit: choking hazards for dysphagia; excessive ultra-processed foods and sugary drinks that worsen behavior/sleep; unnecessary supplements that interact with medicines; long-term restrictive diets without medical oversight. A dietitian can tailor plans around feeding challenges and growth goals. NCBI

---

FAQs

1. Is MED13L syndrome curable? No—care is supportive and symptom-directed. NCBI

2. Did we cause it? Usually not—most variants are de novo and not due to anything parents did. genetics.edu.au

3. How is it diagnosed? By genetic testing (e.g., exome/geno­­me sequencing or chromosomal microarray). NCBI

4. Will every child have heart problems? No—some do; many do not. Screening is guided by the clinician. Nature

5. What about brain scans? Some show nonspecific findings; scans are done only if they change care. NCBI

6. Can speech improve? Yes—with long-term, targeted speech/motor-speech therapy and AAC when needed. PMC

7. Are autism features common? They can occur; behavioral supports and, when appropriate, medications can help. NCBI

8. What is haploinsufficiency? One working copy isn’t enough; this underlies most MED13L cases. search.clinicalgenome.org

9. Is extra MED13L (duplication) the same? Not typically; ClinGen finds no triplosensitivity evidence for classic syndrome. search.clinicalgenome.org

10. What specialists are involved? Genetics, neurology, cardiology (if needed), PT/OT/SLP, dietetics, psychology, special education. NCBI

11. Any clinical trials? Check reputable registries via your genetics team or foundations. The MED13L Foundation

12. Is life expectancy known? Data are limited; outcomes vary with associated medical issues and access to care. NCBI

13. Will another child be affected? A genetics professional can estimate recurrence risk (usually low with de novo variants). genetics.edu.au

14. Which therapies matter most? Early, consistent PT/OT/SLP, AAC, and education supports. NCBI

15. Where can we learn more? GeneReviews/MedlinePlus Genetics; RareChromo guide; MED13L Foundation. The MED13L Foundation+3NCBI+3MedlinePlus+3

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 11, 2025.